Boxer Capital Management LLC Sells 1,161,341 Shares of Replimune Group, Inc. $REPL

Boxer Capital Management LLC lowered its stake in shares of Replimune Group, Inc. (NASDAQ:REPL) by 52.5% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 1,050,000 shares of the company’s stock after selling 1,161,341 shares during the period. Replimune Group makes up approximately 1.4% of Boxer Capital Management LLC’s portfolio, making the stock its 19th biggest holding. Boxer Capital Management LLC’s holdings in Replimune Group were worth $4,400,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets raised its stake in shares of Replimune Group by 37.5% in the second quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock worth $64,000 after purchasing an additional 1,879 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Replimune Group during the second quarter worth $69,000. Russell Investments Group Ltd. grew its holdings in Replimune Group by 3,638.9% during the third quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock worth $33,000 after buying an additional 7,569 shares in the last quarter. Tower Research Capital LLC TRC raised its position in Replimune Group by 2,020.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,692 shares of the company’s stock valued at $90,000 after buying an additional 9,235 shares during the last quarter. Finally, Letko Brosseau & Associates Inc. purchased a new stake in Replimune Group in the 2nd quarter valued at $100,000. 92.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on REPL shares. Wedbush lifted their price objective on shares of Replimune Group from $18.00 to $19.00 and gave the stock an “outperform” rating in a report on Wednesday, February 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Replimune Group in a report on Monday, December 29th. Finally, Piper Sandler raised their price target on shares of Replimune Group from $13.00 to $14.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Replimune Group has an average rating of “Hold” and a consensus price target of $10.00.

Replimune Group Stock Performance

Shares of REPL opened at $7.14 on Friday. The stock has a 50 day moving average of $7.73 and a 200 day moving average of $7.67. The company has a market capitalization of $589.55 million, a price-to-earnings ratio of -2.08 and a beta of 0.72. Replimune Group, Inc. has a 12 month low of $2.68 and a 12 month high of $13.24. The company has a current ratio of 5.60, a quick ratio of 5.60 and a debt-to-equity ratio of 0.33.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported ($0.77) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.08. As a group, sell-side analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.